Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. FDA label
pegvisomant · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pegvisomant | DRUG | - |
Inclusion Criteria: * Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009). Exclusion Criteria: * Switching to other therapeutic methods for acromegaly
Pegvisomant is used for the treatment of acromegaly, a hormonal disorder in which the pituitary gland produces excess growth hormone. It is an endocrine therapy developed by Pfizer, Inc. (ticker PFE) and is given to patients with this condition.
Pegvisomant targets the growth hormone receptor, or GHR. It acts as a receptor antagonist, meaning it blocks the growth hormone receptor rather than activating it. By binding to GHR and blocking signaling, pegvisomant reduces the effects of excess growth hormone in patients with acromegaly.
Pegvisomant is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development of this acromegaly therapy.
Pegvisomant is in Phase 3 clinical development for acromegaly. It is an investigational therapy in this development program, and the Phase 3 trial listed for it has been completed.
Pegvisomant has been studied in the Phase 3 trial NCT00143416, titled Long Term Study With B2036-PEG. That trial enrolled 16 participants with acromegaly in Japan and is completed. It was an uncontrolled study without randomization or double blinding.
Pegvisomant is an investigational therapy in Phase 3 clinical development for acromegaly. The available development information describes a completed Phase 3 trial rather than an approved product, so pegvisomant should be regarded as still in clinical development.